Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase 1 Trial

PURPOSE: This dose-finding phase 1 study investigated the maximum tolerated dose (MTD) and safety of weekly nab-rapamycin in patients with untreatable advanced nonhematologic malignancies. EXPERIMENTAL DESIGN: nab-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a start...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gonzalez-Angulo, Ana M., Meric-Bernstam, Funda, Chawla, Sant, Falchook, Gerald, Hong, David, Akcakanat, Argun, Chen, Huiqin, Naing, Aung, Fu, Siqing, Wheler, Jennifer, Moulder, Stacy, Helgason, Thorunn, Li, Shaoyi, Elias, Ileana, Desai, Neil, Kurzrock, Razelle
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3935482/
https://ncbi.nlm.nih.gov/pubmed/24089446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3110
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak